XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1495-1503

  Hatch, Stephanie B ^a   Swift, Lonnie P ^a   Caporali, Simona ^b   Carter, Rebecca ^a   Hill, Esme J ^a   Macgregor, Thomas P ^a   D'Atri, Stefania ^b   Middleton, Mark R ^a   McHugh, Peter J ^a   Sharma, Ricky A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

cell cycle; cytotoxic chemotherapy; DNA repair; tissue biomarker

Indexed keywords

CARBOPLATIN; ENDONUCLEASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN; UNCLASSIFIED DRUG; XPF PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DNA CROSS LINKING; DOUBLE STRANDED DNA BREAK; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT;

EID: 84891829580     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28454     Document Type: Article

References (33)

1. Cancer Research UK. Cancer Statistics. Available at: http://www. cancerresearchuk.org/cancer-info/cancerstats/types/skin, 2010 [cited 2013]. Accessed on August 9, 2013.
2. Curado MP, Edwards B, Shin HR, et al., eds. Cancer incidence in five continents, vol. 9. Lyon, France: IARC, 2007.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
7. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol, in press.
8. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
9. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-34.
10. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008; 27: 565-73.
11. Song L, Robson T, Doig T, et al. DNA repair and replication proteins as prognostic markers in melanoma. Histopathology 2013; 62: 343-50.
12. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
13. Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998; 4: 1021-9.
14. Mohammed MQ, Retsas S,. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs 2000; 11: 859-63.
15. Locke F, Clark JI, Gajewski TF,. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol 2010; 65: 509-14.
16. McClay EF, Bessudo A, Frakes L, et al. A phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma: ASCO; Available at: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=55&abstractID=34137, 2008 [cited 2013]. Accessed on July 1, 2013.
17. Swift LP, Cutts SM, Rephaeli A, et al. Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol Cancer Ther 2003; 2: 189-98.
18. De Silva IU, McHugh PJ, Clingen PH, et al. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002; 30: 3848-56.
19. Levati L, Pagani E, Romani S, et al. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 2011; 24: 538-50.
20. Carta F, Demuro PP, Zanini C, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005; 15: 235-44.
21. Wang AT, Sengerova B, Cattell E, et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev 2011; 25: 1859-70.
22. Almeida GM, Duarte TL, Steward WP, et al. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) 2006; 5: 219-25.
23. Saris CP, van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763-9.
24. Voland C, Bord A, Peleraux A, et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006; 5: 2149-57.
25. Hoy CA, Thompson LH, Mooney CL, et al. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 1985; 45: 1737-43.
26. Andersson BS,. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 1996; 38: 406-16.
27. Sengerova B, Wang AT, McHugh PJ,. Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair. Cell Cycle 2011; 10: 3999-4008.
28. Rahn JJ, Adair GM, Nairn RS,. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen 2010; 51: 567-81.
29. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004; 24: 5776-87.
30. Al-Minawi AZ, Saleh-Gohari N, Helleday T,. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 2008; 36: 1-9.
31. Arora S, Kothandapani A, Tillison K, et al. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 2010; 9: 745-53.
32. Graf N, Ang WH, Zhu G, et al. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem 2011; 12: 1115-23.
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.